rhIGF-1 Explored for Growth Failure in Children with Primary IGF-1 Deficiency
Background
Children suffering from primary Insulin-Like Growth Factor-1 (IGF-1) deficiency experience severe growth failure and short stature due to their bodies' inability to produce sufficient IGF-1, a crucial hormone for growth and development. This condition significantly impacts their physical development and overall quality of life. Current therapeutic options are limited, highlighting a critical need for effective interventions. This Phase 3 study addresses the knowledge gap regarding the optimal dosing and long-term efficacy of recombinant human IGF-1 (rhIGF-1) as a treatment for this specific population.
Study Design
Results
This Phase 3 trial was designed to rigorously assess the impact of rhIGF-1 on growth parameters in prepubertal children with primary IGF-1 deficiency; however, specific efficacy results detailing growth velocity, height changes, or IGF-1 levels are not provided within this clinical trial registration record. The study successfully enrolled 137 participants, demonstrating the feasibility of conducting a large-scale trial for this rare condition. The inclusion of multiple dosing arms (40 μg/kg BID, 80 μg/kg BID, 120 μg/kg BID) suggests an intent to identify an optimal therapeutic window for mecasermin. The protocol amendment to increase the dose for the lowest arm indicates an adaptive approach to treatment optimization during the trial's progression. > This Phase 3 trial successfully enrolled 137 prepubertal children to investigate rhIGF-1 (mecasermin) as a treatment for primary IGF-1 deficiency, with the primary objective being to evaluate its efficacy and safety in improving growth outcomes. The study's completion in 2008 suggests that comprehensive data analysis would have followed, though not detailed here.
Why It Matters
The successful completion of this Phase 3 trial is a significant step towards developing an effective treatment for primary IGF-1 deficiency, a condition with limited therapeutic options. rhIGF-1 (mecasermin) holds substantial promise as a targeted therapy, directly addressing the underlying hormonal deficit responsible for growth failure. If proven effective, this treatment could dramatically improve the growth trajectory and overall health of affected children, potentially becoming a new standard of care. The findings from such a large-scale study are crucial for regulatory approval processes and for informing clinical practice, paving the way for broader access to this vital medication.